MannKind Corporation (NASDAQ:MNKD) is running higher again Wednesday as a short-squeeze might be in effect. Shares of MannKind have closed higher for 17 out of the last 21 trading sessions, rising about 63 percent in the process. Short interest was last at 29.2 percent of float, or about 68.0 million shares. MannKind Corporation (NASDAQ:MNKD) weekly performance is 29.01%. On last trading day company shares ended up $10.54. Analysts mean target price for the company is $8.58. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average (SMA50) is 57.99%.
Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) , a biopharmaceutical company focused on developing therapies to treat schizophrenia and sleep disorders, surged as much as 25% after announcing that its non-24-sleep-wake disorder drug Hetlioz was accepted for marketing authorization evaluation by the European Medicines Agency. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares advanced 25.35% in last trading session and ended the day on $12.56. VNDA return on assets is -31.80%.Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) quarterly performance is -18.12%.
Clovis Oncology Inc. (NASDAQ:CLVS) CEO Patrick Mahaffy told CNBC he’s been the underdog for most of his career. “It probably would be fun to be an overdog one time,” he said in an interview Monday from the American Society of Clinical Oncology meeting, where the biotech company presented data on its experimental drug for lung cancer, CO-1686 that will compete with a similar one from British drug giant. Clovis Oncology Inc. (NASDAQ:CLVS) shares moved up 0.44% in last trading session and was closed at $38.40, while trading in range of $36.11 – $38.82. Clovis Oncology Inc. (NASDAQ:CLVS) year to date (YTD) performance is -36.29%.
Transcept Pharmaceuticals, Inc. (NASDAQ:TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, on 5 may announced financial results for the three months ended March 31, 2014. Net loss for the quarter ended March 31, 2014 was approximately $2.8 million, or $0.15 per share (basic and diluted), compared to net loss of approximately $10.5 million, or $0.56 per share (basic and diluted), for the quarter ended March 31, 2013. Transcept Pharmaceuticals Inc. (NASDAQ:TSPT) ended the last trading day at $2.06. Company weekly volatility is calculated as 5.27% and price to cash ratio as 0.55.Transcept Pharmaceuticals Inc. (NASDAQ:TSPT) showed a negative weekly performance of -35.22%.
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, on 31 may announced plans for the clinical development of sapacitabine in a second potential indication for patients with myelodysplastic syndromes (MDS) after treatment failure of front-line hypomethylating agents. Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) weekly performance is -10.40%. On last trading day company shares ended up $2.93. Analysts mean target price for the company is $9.67. Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) distance from 50-day simple moving average (SMA50) is -12.69%.